Clinical Adoption Ceirbell’s FDA 510(k) cleared point-of-care EEG platform is already deployed in U.S. ICUs and emergency departments and is actively seeking to accelerate adoption across hospitals, signaling a large addressable market and opportunities for hospital systems, distributors, and integration partners.

Strategic Partnerships Given the emphasis on rapid deployment and acute care monitoring, there are strong sales opportunities partnering with healthcare providers, hospital networks, and AI/tech-enabled clinical services to expand indications such as large vessel occlusion stroke detection and ESE monitoring.

Expansion & Growth Ceribell is expanding leadership and representation in key markets, evidenced by executive hires in marketing and people operations and public visibility at major investor conferences, which can open doors with procurement teams and informatics leads through enhanced market presence.

AI-Driven Differentiation The AI-powered, portable EEG solution differentiates Ceribell from traditional EEG providers, presenting upsell opportunities to hospitals seeking faster diagnosis, continuous monitoring, and potential cost savings from reduced ICU stays and quicker seizure management.

Financial & Funding Signals With notable revenue between fifty and one hundred million and recent funding activity, Ceribell demonstrates financial momentum that can support customer pilots, larger-volume deployments, and co-development initiatives with health systems and device distributors.